Alpha Cognition (NASDAQ:ACOG) Issues Quarterly Earnings Results

Alpha Cognition (NASDAQ:ACOG) issued its quarterly earnings data on Thursday. The company reported ($0.40) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.01), Zacks reports. The firm had revenue of $6.00 million for the quarter, compared to the consensus estimate of $4.38 million. Alpha Cognition had a negative net margin of 232.23% and a negative return on equity of 58.35%.

Here are the key takeaways from Alpha Cognition’s conference call:

• ZUNVEYL net product revenue rose 71% sequentially to approximately $6 million in Q2 2026, with demand increasing each month and June marking the strongest month to date.
• Commercial adoption continued to deepen, with 1,347 active prescribers, 1,095 nursing homes placing prescriptions, and repeat utilization from approximately 76% of writers and 81% of prescribing homes.
• Management highlighted positive BEACON findings across cognition, neuropsychiatric symptoms, activities of daily living, and polypharmacy, while CONVERGE data is expected in Q3 2026 and RESOLVE remains on track to complete in Q2 2027.
• Payer and formulary expansion remains the largest near-term constraint; broad activation has been slower than expected, with coverage holding at roughly 74% and no significant formulary wins reported in Q2.
• The company reduced 2026 operating-expense guidance to $50 million-$54 million from $54 million-$58 million, ended Q2 with $41.4 million in cash, and reiterated its target of reaching operating profitability in 2027.

Alpha Cognition Trading Up 6.3%

NASDAQ ACOG opened at $9.18 on Friday. The stock has a market cap of $199.78 million, a PE ratio of -6.44 and a beta of 2.31. The stock’s 50 day moving average is $7.68 and its 200 day moving average is $6.50. Alpha Cognition has a 12 month low of $4.50 and a 12 month high of $10.00.

Institutional Investors Weigh In On Alpha Cognition

Several institutional investors have recently modified their holdings of ACOG. Geode Capital Management LLC purchased a new stake in Alpha Cognition in the 2nd quarter valued at about $112,000. Massar Capital Management LP purchased a new position in shares of Alpha Cognition in the 2nd quarter worth approximately $116,000. Two Sigma Investments LP purchased a new stake in shares of Alpha Cognition during the 3rd quarter valued at $148,000. Connective Capital Management LLC purchased a new position in Alpha Cognition during the 3rd quarter worth $312,000. Finally, Marshall Wace LLP purchased a new stake in Alpha Cognition in the second quarter valued at about $600,000.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on the stock. Wall Street Zen lowered shares of Alpha Cognition from a “hold” rating to a “sell” rating in a research note on Saturday, May 2nd. Maxim Group assumed coverage on Alpha Cognition in a research note on Friday, May 29th. They issued a “buy” rating and a $12.00 target price on the stock. Raymond James Financial initiated coverage on Alpha Cognition in a research report on Friday, July 10th. They issued an “outperform” rating and a $20.00 price target for the company. Craig Hallum started coverage on shares of Alpha Cognition in a research note on Friday, April 17th. They set a “buy” rating and a $14.00 price objective for the company. Finally, HC Wainwright reissued a “buy” rating and set a $18.00 price target on shares of Alpha Cognition in a research report on Friday, May 22nd. Four investment analysts have rated the stock with a Buy rating, According to MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $16.00.

About Alpha Cognition

Alpha Cognition, Inc is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer’s Dementia and Amyotrophic Lateral Sclerosis. The company was founded in 2000 and is headquartered in Vancouver, Canada.